NCT03519945: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
- State
- Under way
- Phase
- Phase 3
- People
- 1,058 taking part
- Started
- 18 Jul 2018
- Primary completion
- 4 Mar 2026
- Arms
- Mirikizumab
- Results
- None posted
- 9 May 2018: Trial registered
- 18 Jul 2018: Trial started